Drug intelligence / Profile preview

AC-11

Development stage
Unknown
Lead developer
Optigenex
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral, Topical
01

Overview

AC-11 is a patented, aqueous botanical extract derived from the Amazonian vine *Uncaria tomentosa* (cat's claw), developed and trademarked by Optigenex. It is standardized to contain a minimum of 8% Carboxy Alkyl Esters (CAEs), which are identified as the primary bioactive constituents responsible for its therapeutic effects. Unlike standard cat's claw extracts, AC-11 is produced through a proprietary hot water extraction and ultra-filtration process that ensures it is free of indole alkaloids and maintains a low molecular weight (under 10,000 Daltons). The compound is primarily recognized for its ability to enhance natural DNA repair mechanisms, particularly in response to oxidative stress and UV radiation. Additionally, it demonstrates anti-inflammatory activity by inhibiting pro-inflammatory cytokines, supports immune function, stimulates the production of type III collagen, and has been shown to increase telomere length. It is utilized in both oral nutraceuticals and topical cosmetic formulations for general wellness and anti-aging applications.

Brand names
AC-11AC11AC 11
Other names
Uncaria tomentosa extractcat's claw extractcarboxy alkyl esters
02

Targets

NF-κBtelomeric G4 (Telomeric DNA G-quadruplex)DNA

Beyond the preview

Go deeper on AC-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC-11.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call